VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta

Neurology

Volumn 49, Issue 4, 1997, Pages 1111-1116

  Calabresi, P A ^a,b,c,d,e   Pelfrey, C M ^a,b,c,d,e   Tranquill, L R ^a,b,c,d,e   Maloni, H ^a,b,c,d,e   McFarland, H F ^a,b,c,d,e  

^a Ncuroimmunology Branch   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c Department of Pathology ^*  (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1 INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON BETA SERINE; METHYLPREDNISOLONE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0030726157     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.4.1111     Document Type: Article

References (31)

1. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10: 153-187.
2. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Grit Rev Clin Lab Sei 1995;32:121-182.
3. Williams KG, Ulvestad E, Hickey WF. Immunology of multiple sclerosis. Clin Neurosci 1994;2:229-245.
4. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76: 301-314.
5. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993;11:767-804.
6. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-2101.
7. Pober JS, Gimbrone MA, Lapierre LA, et al. Overlapping patterns of activation of human endothelial cells by interleukin-1, tumor necrosis factor, and immune Interferon. J Immunol 1986;137:1893-1896.
8. McCarron RM, Wang L, Racke RK, McFarlin DE, Spatz M. Cytokine-regulated adhesion between encephalitogenic T lymphocytes and cerebrovascular endothelial cells. J Neuroimmunol 1992;43:23-30.
9. Baron J, Madri J, Ruddle N, et al. Surface expression of a4 integrin by CD4+ cells is required for their entry into brain parenchyma. J Exp Med 1993;177:57-68.
10. Dustin M, Springer TA. Lymphocyte function associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1988;107:321-331.
11. McFarland HF. The multiple sclerosis lesion. Ann Neurol 1995;37:419-421.
12. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424435.
13. Kermode AG, Thompson JA, Tofts PS, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenesis and clinical implications. Brain 1990;113:1477-1489.
14. Filippi M, Horsfield MA, Tofts PS, et al. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995;118:1601-1612.
15. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadolinium enhancing MRI lesions. Ann Neurol 1993; 33:480-489.
16. Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34:661-669.
17. McFarland HF, Frank JA, Albert PS, et al. Using gadoliniumenhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758766.
18. The IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993;43:655-661.
19. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993;43:662-667.
20. Stone LA, Frank JA, Albert PS, et al. The effect of interferonbeta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsingremitting multiple sclerosis. Ann Neurol 1995;37:611-619.
21. Calabresi PA, Tranquill LR, Dambrosia JA, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with Interferon β-lb. Ann Neurol 1997;41:669-674.
22. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
23. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
24. Kitani A, Nakashima N, Matsuda T, et al. T cells bound by vascular cell adhesion molecule-1/CD106 in synovial fluid in rheumatoid arthritis. J Immunol 1996;156:2300-2308.
25. Jakubowski A, Ehrenfels BN, Pepinsky RB, Burkly LC. Vascular cell adhesion molecule-lg fusion protein selectively targets activated a-4-integrin receptors in vivo. J Immunol 1995; 155:938-946.
26. Leca G, Mansur SE, Bensussan A. Expression of VCAM-1 (CD106) by a subset of TCR -yS-bearing lymphocyte clones. J Immunol 1995;154:1069-1077.
27. Leppert D, Waubant E, Burk MR, et al. Interferon beta-lb inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-852.
28. Stuve O, Dooley NP, Uhm JH, et al. Interferon β-lb decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-863.
29. Calabresi PA, Stone LA, Bash CN, Frank JA, McFarland HF. Interferon beta results in immediate reduction of contrastenhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997;48:1446-1448.
30. Yednock TA, Canon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin. Nature 1992;356:63-66.
31. Kent SJ, Karlik SJ, Rice GP, Horner HC. A monoclonal antibody to alpha 4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig. J Magn Reson Imaging 1995;5:535-540.